{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T08:15:12Z","timestamp":1782375312192,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.clgc.2014.03.002","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T02:32:48Z","timestamp":1395109968000},"page":"262-269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity"],"prefix":"10.1016","volume":"12","author":[{"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Foreshew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0703-2959","authenticated-orcid":false,"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Lampron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Cerbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cora N.","family":"Sternberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2014.03.002_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.hoc.2011.06.001","article-title":"Renal cell carcinoma","volume":"25","author":"Choueiri","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clgc.2014.03.002_bib2","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0094-0143(03)00056-9","article-title":"Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease","volume":"30","author":"Janzen","year":"2003","journal-title":"Urol Clin N Am"},{"key":"10.1016\/j.clgc.2014.03.002_bib3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/1758834010361470","article-title":"Updates on novel therapies for metastatic renal cell carcinoma","volume":"2","author":"Courtney","year":"2010","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib4","doi-asserted-by":"crossref","first-page":"6290S","DOI":"10.1158\/1078-0432.CCR-sup-040025","article-title":"The von Hippel-Lindau tumor suppressor gene and kidney cancer","volume":"10","author":"Kaelin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2014.03.002_bib5","first-page":"757908","article-title":"Effects of HIF-1alpha and HIF2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts","volume":"2010","author":"Biswas","year":"2010","journal-title":"J\u00a0Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0076-6879(07)35019-2","article-title":"The von Hippel-Lindau tumor suppressor protein: an update","volume":"435","author":"Kaelin","year":"2007","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.clgc.2014.03.002_bib7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.14694\/EdBook_AM.2012.32.25","article-title":"The evolving landscape of metastatic renal cell carcinoma","author":"Heng","year":"2012","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clgc.2014.03.002_bib8","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2014.03.002_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.cra4502","article-title":"Patient preference between pazopanib (Paz) and sunitinib (Sun): results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma (mRCC) - PISCES study, NCT 01064310","volume":"30","author":"Escudier","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib10","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(11)70042-0","article-title":"NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma","volume":"12","author":"Griffiths","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","article-title":"NCCN clinical practice guidelines in oncology: kidney cancer","volume":"7","author":"Motzer","year":"2009","journal-title":"J\u00a0Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2014.03.002_bib12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.eururo.2011.10.032","article-title":"Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?","volume":"61","author":"Sonpavde","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2014.03.002_bib13","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-13-0491","article-title":"The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma","volume":"19","author":"Choueiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2014.03.002_bib14","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1053\/j.seminoncol.2013.05.010","article-title":"Combination therapy in metastatic renal cell cancer","volume":"40","author":"Ravaud","year":"2013","journal-title":"Semin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib15","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urology.2009.12.031","article-title":"Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy","volume":"76","author":"Vickers","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2014.03.002_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2014.03.002_bib17","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2014.03.002_bib18","doi-asserted-by":"crossref","unstructured":"Hutson TE, Escudier B, Esteban E, et al. Temsirolimus vs sorafenib as second line therapy in metastatic renal cell carcinoma: results from INTORSECT trial. The 37th European Society of Medical Oncology Congress 2012 (abstract LBA22_PR).","DOI":"10.1016\/S0923-7534(20)34327-1"},{"key":"10.1016\/j.clgc.2014.03.002_bib19","doi-asserted-by":"crossref","first-page":"E250","DOI":"10.1111\/j.1464-410X.2011.10186.x","article-title":"Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases","volume":"108","author":"Porta","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2014.03.002_bib20","first-page":"29","article-title":"Sequential sorafenib and sunitinib for renal cell carcinoma","volume":"182","author":"Sablin","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2014.03.002_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.24009","article-title":"Sequential therapy with sorafenib and sunitinib in renal cell carcinoma","volume":"115","author":"Dudek","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2014.03.002_bib22","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","article-title":"Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis","volume":"54","author":"Eichelberg","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2014.03.002_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5123","article-title":"A\u00a0multicenter prospective trial of sorafenib\u00a0in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) refractory to prior sunitinib or bevacizumab","volume":"26","author":"Shepard","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib24","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1200\/JCO.2009.22.6480","article-title":"Phase II study of sorafenib in patients\u00a0with sunitinib-refractory metastatic renal cell cancer","volume":"27","author":"Di Lorenzo","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib25","first-page":"172","article-title":"Sequencing systemic therapies in advanced RCC","volume":"2013","author":"Powles","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib26","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1535-6108(03)00187-9","article-title":"TSC2 regulates VEGF through mTOR-dependent and -independent pathways","volume":"4","author":"Brugarolas","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2014.03.002_bib27","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.4504","article-title":"Record-3: phase II randomized trial comparing sequential first-line everolimus (EVE) and second-line sunitinib (SUN) versus first-line SUN and second-line EVE in patients with metastatic renal cell carcinoma (mRCC)","volume":"31","author":"Motzer","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 10","key":"10.1016\/j.clgc.2014.03.002_bib28","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1002\/cncr.24235","article-title":"Novel therapeutics for metastatic renal cell carcinoma","volume":"115","author":"Hutson","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2014.03.002_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.critrevonc.2010.07.018","article-title":"Sequential use of targeted agents in the treatment of renal cell carcinoma","volume":"77","author":"Hutson","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2014.03.002_bib30","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","article-title":"Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer","volume":"25","author":"Bukowski","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2014.03.002_bib31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/annonc\/mdr533","article-title":"Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy","volume":"23","author":"Heng","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767314000512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:23:14Z","timestamp":1761564194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767314000512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1558767314000512"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2014.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}